NEW YORK CITY (dpa-AFX) - Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE)
Thursday announced positive 6-month follow up data from a Phase 1b study
evaluating vepdegestrant in combination with Pfizer's breast cancer drug
Palbociclib in heavily pre-treated breast cancer patients.

The Phase 1b study was designed to assess the safety, tolerability, and
anti-tumor activity of vepdegestrant in combination with palbociclib in patients
with heavily pre-treated breast cancer. Initial positive data were presented at
San Antonio Breast Cancer Symposium (SABCS) in December 2023.

After six months of additional follow-up, the combination therapy could achieve
clinical benefit rate of 63%, overall response rate of 41.9%, and median
progression-free survival of 11.2 months. Additionally, safety profile of
vepdegestrant in combination with palbociclib was consistent with data
previously reported at SABCS in December last year.

Vepdegestrant, co-developed by Arvinas and Pfizer, is being evaluated as a
monotherapy in the ongoing Phase 3 VERITAC-2 trial and in combination with
palbociclib in the ongoing Phase 3 VERITAC-3 trial in patients with breast
cancer.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX